Entellus Medical (NASDAQ:ENTL) target bumped up to $26.00, issued a ratings update earlier today by Deutsche Bank
- Updated: October 6, 2016
Yesterday Entellus Medical (NASDAQ:ENTL) traded -1.16% lower at $22.12. The company’s 50-day moving average is $19.71 and its 200-day moving average is $18.01. The last stock close price is up 22.81% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 107,488 shares of Entellus Medical exchanged hands, up from an avg. volume of 40,134
Stating a possible upside of 0.18%, Deutsche Bank bumped up the target of Entellus Medical (NASDAQ:ENTL) to $26.00
Recent Performance Chart
Entellus Medical has with a one year low of $13.72 and a one year high of $22.57 and has a market capitalization of $0.
General Company Details For Entellus Medical (NASDAQ:ENTL)
Entellus Medical, Inc. is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company's XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation. The Company's XprESS family of products is used to treat patients with inflammation of the frontal, ethmoid, sphenoid and maxillary sinuses. Its XprESS Multi-Sinus Dilation family of products consists of its XprESS Pro device, its XprESS LoProfile device and its XprESS Ultra device. The Company's PathAssist tools provide ENT physicians with a way to confirm sinus location and XprESS device placement. Its FocESS Sinuscopes provide ENT physicians with a solution for endoscopic visualization during a sinus procedure.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.